Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku’s Filing of Remicade Biosimilar Heralds Age of Major Biologic Follow-Ons
September 12, 2013
- Ono to Set Up New Strategic Division for Nivolumab
September 12, 2013
- Merck Serono Launches Human Growth Hormone Preparation Saizen 12 mg Subcutaneous Injection
September 12, 2013
- Nichi-Iko, BioLab Tie Up on Generic Business in Thailand
September 11, 2013
- MTPC Subsidiary in Indonesia to Construct New Production Facility
September 10, 2013
- Kyowa Kirin to Establish New Research Center in Singapore, Conduct Joint Research with Local Research Institutes
September 10, 2013
- InCROM Subsidiary in Shanghai Set to Become Subsidiary of Chinese Pharma Giant, Aims for Business Expansion
September 10, 2013
- Wholesalers to Stress that Medical Institutions Will Not Have to Incur Any Losses Due to Consumption Tax Hike
September 10, 2013
- Novartis AG Takes Retraction of JIKEI Paper “Seriously”; Problems Partly Traced to “Limited Understanding” about Investigator-Led Trials
September 9, 2013
- Shionogi Launches Irtra Combination Tablets LD/HD
September 9, 2013
- Novartis Appoints Former AbbVie Exec to Lead Medical Scientific Affairs
September 6, 2013
- Otsuka Holdings President Has High Hopes for Rapid Lead Compound Discovery
September 6, 2013
- Otsuka to Buy US Biotech Firm Astex for US$886 Million
September 6, 2013
- Takeda Mulls Taking Stab at Generic Biz in Japan via ASKA
September 6, 2013
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…